Neuralink Secures $280 Million for Human Brain Implant Trials

Tweet

Elon Musk’s innovative medtech venture, Neuralink, is making significant strides in its mission to pioneer brain implant technology. Following reported FDA approval for human trials, the company has successfully raised an additional $280 million in funding, bolstering its total investment to an impressive $643 million.

In a recent announcement, Neuralink extended an invitation to individuals with the skills and passion to contribute to “engineering challenges aimed at restoring vision and mobility.”

Neuralink initiated the FDA approval process late last year, unveiling their ambitious vision to develop a “generalized input/output device” capable of seamlessly interfacing with all aspects of the human brain. Elon Musk, during a “show and tell” event last year, emphasized the company’s commitment to meticulous preparation before implanting any devices in humans. He even expressed his willingness to personally undergo the implantation of a Neuralink device to demonstrate his confidence in the technology’s safety and efficacy.

In May, Musk disclosed that, following an initial reported rejection, the FDA had granted approval for Neuralink’s planned trials. However, there was some uncertainty as the Associated Press noted that Neuralink was not listed in the U.S. clinical trials database, and the company had yet to divulge specific trial details.

Neuralink is currently actively recruiting interns and team members to bolster its diverse workforce. Opportunities span a range of disciplines, including mechanical engineering, animal care, research services, brain interfaces, core software development, and surgical robotics. This call for talent underscores Neuralink’s commitment to assembling a skilled team capable of advancing the frontier of neural technology and enhancing the lives of those with neurological challenges.

Bianca Van der Watt